Here, we have studied the methylation status of the MGMT promoter in histological tumor samples obtained from patients with LMS treated with dacarbazine, aiming to ameliorate dacarbazine use in these STS and to find out if the methylation of MGMT correlates with clinical response. This evidence concerns the gene MGMT and telomere syndrome.